Recombinant human autoantigen Scl-70

A self-antigen, nucleic acid sequence technology, applied in the field of recombinant human self-antigen, can solve the problems of difficulty in extraction and purification of natural human antigens, limited development of ANA detection reagents, and difficulty in obtaining high-purity samples, and achieves strong reactivity, easy expression and The effect of purification and low cost of use

Inactive Publication Date: 2015-11-18
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The extraction and purification of natural human autoantigens is difficult, and it is difficult to obtain high-purity samples, resulting in high cost of use. These problems limit the development of ANA detection reagents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant human autoantigen Scl-70
  • Recombinant human autoantigen Scl-70
  • Recombinant human autoantigen Scl-70

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: IPTG concentration is 0.2mM

[0033] The recombinant expression plasmid was introduced into Escherichia coli BL21 competent cells, and positive transformants were selected and inoculated in LB liquid medium containing kanamycin, and cultured overnight at 37°C on a shaking table. The next day, inoculate in 300ml of fresh same culture medium at a ratio of 1:100, culture on a shaker at 37°C until the A600 is 0.4-0.6, put the bacteria solution on ice for 30min, then add IPTG to a final concentration of 0.2mM, and overnight at 20°C induced expression.

Embodiment 2

[0034] Embodiment 2: IPTG concentration is 0.6mM

[0035] The recombinant expression plasmid was introduced into Escherichia coli BL21 competent cells, and positive transformants were selected and inoculated in LB liquid medium containing kanamycin, and cultured overnight at 37°C on a shaking table. The next day, inoculate 300ml of the same fresh culture medium at a ratio of 1:100, culture on a shaker at 37°C until the A600 is 0.4-0.6, put the bacteria in an ice bath for 30min, then add IPTG to a final concentration of 0.6mM, and overnight at 20°C induced expression.

Embodiment 3

[0036] Embodiment 3: IPTG concentration is 1.0mM

[0037] The recombinant expression plasmid was introduced into Escherichia coli BL21 competent cells, and positive transformants were selected and inoculated in LB liquid medium containing kanamycin, and cultured overnight at 37°C on a shaking table. The next day, inoculate 300ml of the same fresh culture medium at a ratio of 1:100, culture on a shaker at 37°C until the A600 is 0.4-0.6, put the bacteria in an ice bath for 30min, then add IPTG to a final concentration of 1.0mM, and overnight at 20°C induced expression.

[0038] The expression results induced by different IPTG concentrations are as follows: figure 1 shown. figure 1 Middle, M: Protein Marker, the size from top to bottom is 130KD, 95KD, 72KD, 55KD, 43KD, 34KD, 26KD, 17KD, 10KD, 1: blank control without adding IPTG, 2: adding 0.2mMIPTG, 3: adding 0.6mMIPTG, 4: add 1.0mMIPTG

[0039] from figure 1 It can be seen that after adding IPTG, the recombinant human auto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a recombinant human autoantigen Scl-70. The core amino acid sequence of the antigen is shown as SEQ ID No:1, at least one end of the core amino acid sequence is connected to a protective peptide. The recombinant human autoantigen provided by the invention has short peptide chain, and is easy to express and purify. A lot of high purity antigens can be obtained at a time, the use cost is low, and the economic benefit is good. The recombinant antigen has very strong activity, thus being conducive to development of ANA detection reagents.

Description

technical field [0001] The invention relates to a recombinant human autoantigen. Background technique [0002] Autoimmune diseases (Autoimmune Diseases, AID) generally refer to the body's immune effector cells or immune effector molecules, which have abnormal immune responses against their own tissues or cells, resulting in tissue damage or dysfunction. Systemic system, a disease that seriously endangers human health, has a high disability rate, and a high fatality rate. [0003] Among the various detection items of AID disease, since antinuclear antibody (ANA) is closely related to AID and is an important target of autoimmune response, antinuclear antibody detection has always been in an important position in AID disease and is a clinical Very important screening test. With the continuous deepening of people's understanding, the definition of antinuclear antibody (Antinuclearantibody, ANA) has been extended from the original traditional nucleus to the current whole cell, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47C12N15/12
CPCC07K14/47
Inventor 裘宇容李海侠李欣陈泳钗王小明夏坤
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap